iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 3,750 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the transaction, the chief executive officer directly owned 2,198,750 shares of the company's stock, valued at $196,040,550. The trade was a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Stock Performance
NASDAQ:IRMD opened at $83.44 on Friday. The company has a 50-day moving average of $96.69 and a 200-day moving average of $93.87. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 47.68 and a beta of 1.11. iRadimed Corporation has a 52 week low of $50.31 and a 52 week high of $107.90.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts forecast that iRadimed Corporation will post 1.94 EPS for the current year.
iRadimed Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were given a dividend of $0.20 per share. This is an increase from iRadimed's previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.0%. iRadimed's dividend payout ratio is 45.71%.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the stock. Roth Mkm reiterated a "buy" rating and set a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reiterated a "buy" rating and set a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $120.00.
View Our Latest Research Report on iRadimed
Institutional Investors Weigh In On iRadimed
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its position in iRadimed by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider's stock valued at $6,848,000 after acquiring an additional 33,072 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in iRadimed in the 3rd quarter valued at about $422,000. Tudor Investment Corp ET AL acquired a new stake in iRadimed in the 3rd quarter valued at about $666,000. R Squared Ltd acquired a new stake in iRadimed in the 3rd quarter valued at about $308,000. Finally, Nkcfo LLC acquired a new stake in iRadimed in the 3rd quarter valued at about $96,000. Institutional investors and hedge funds own 92.34% of the company's stock.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
